Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLIS TechnologiesNZSE:BLT Debt-to-EBITDA is 0.38 as of Mar. 2026, which is 23% above its 10-year median of 0.31. The stock has 5 warning signs investors should review. Among 314 Biotechnology companies, BLIS Technologies ranks better than 74.2% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BLIS Technologies's Debt-to-EBITDA or its related term are showing as below:
NZSE:BLT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83 Med: 0.31 Max: 0.89
Current: 0.35
During the past 13 years, the highest Debt-to-EBITDA Ratio of BLIS Technologies was 0.89. The lowest was -0.83. And the median was 0.31.
NZSE:BLT's Debt-to-EBITDA is ranked better than 74.2% of 314
companies
in the Biotechnology industry
Industry Median: 1.41
vs NZSE:BLT: 0.35
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BLIS Technologies Debt-to-EBITDA Related Terms
BLIS Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BLIS Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
BLIS Technologies (NZSE:BLT) has a Debt-to-EBITDA of 0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BLIS Technologies. This is 23% above median its historical median of 0.31. According to the industry distribution chart, BLIS Technologies ranks #81 out of 314 companies in the Biotechnology industry, placing it in the top 25.8%.
Is BLIS Technologies' Debt-to-EBITDA too high?
BLIS Technologies' current Debt-to-EBITDA of 0.38 is 23% above median its 10-year median of 0.31. The Biotechnology industry median Debt-to-EBITDA is 1.41. BLIS Technologies' value of 0.38 is 73% below this industry median. Based on the distribution chart, BLIS Technologies ranks #81 out of 314 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #81 out of 314 companies for Debt-to-EBITDA. This puts BLIS Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 1.41. BLIS Technologies' value of 0.38 is 73% below this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 1.41, BLIS Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.41, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Debt-to-EBITDA of 0.38 is 73% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BLIS Technologies. For the Biotechnology industry, the median Debt-to-EBITDA is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Debt-to-EBITDA is 0.38, which is 23% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 5% below its estimated fair value. The current Debt-to-EBITDA is 0.38, which is 23% above median its 10-year median of 0.31 and 73% below the Biotechnology industry median of 1.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 
